The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation
Open accessAbstract
One hundred patients, 54 with acute myelogenous leukemia (AML) and 46 with acute lymphoblastic leukemia (ALL), considered to be in the end stages of their disease, after combination chemotherapy were treated by marrow transplantation. All patients were given a marrow graft from an HLA-identical sibling after receiving 1000-rad total body irradiation (TBI). One group of 43 patients was given cyclophosphamide (CY), 60 mg/kg on each of 2 days, 5 and 4 days before TBI. In a second group of 31 patients, additional chemotherapy was given before CY and TBI. In a third group of 19 patients, BCNU was given before CY and TBI. A fourth group of 7 patients received other chemotherapy regimens before TBI. Six patients died 3–17 days after marrow infusion without evidence of engraftment. Ninety-four patients were engrafted and only one patient rejected the graft. Thirteen patients are alive with a marrow graft, on no maintenance antileukemic therapy, and without recurrent leukemia 1–4 1/2 yr after transplantation. Three have chronic graft-versus-host disease (GVHD). Four patients are alive 1 1/2 - 3 1/2 yr after grafting but have had a relapse of their leukemia. Of 93 evaluable patients, 19 did not develop GVHD and 24 developed very mild GVHD. Fifty patients developed moderate to severe GVHD, and 40 of these were treated with antithymocyte globulin. Interstitial pneumonia occurred in 54 patients and was the primary cause of death in 34. Interstitial pneumonia often occurred in association with GVHD and the most common etiologic agent was cytomegalovirus. A total of 31 patients have had a relapse of leukemia. There was no definite correlation between relapse of leukemia and the presence or absence of GVHD. The relapse rate appeared to be relatively constant over the first 2 yr and was extremely low after that time. Neither survival nor leukemic relapse appeared to be influenced by the type of leukemia nor by the preparative chemotherapy regimen given before TBI. Patients in fair clinical condition at the time of transplantation showed significantly longer survival times than patients in poor condition (p = 0.001). This observation, coupled with the observation that some patients may be cured of their disease, indicates that marrow transplantation should now be undertaken earlier in the management of patients with acute leukemia who have an HLA- matched sibling marrow donor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Bone-Marrow Transplantation: (First of Two Parts)
Thomas, E. D., Storb, R., Clift, R. A., Fefer, A., Johnson, F. L., Neiman, P. E., Lerner, K. G., Glucksberg, H., & Buckner, C. D. (1975) · New England Journal of Medicine · doi:10.1056/nejm197504172921605 · Cited by 1,693
Self-citationMETHOTREXATE REGIMENS FOR CONTROL OF GRAFT-VERSUS-HOST DISEASE IN DOGS WITH ALLOGENEIC MARROW GRAFTS
Storb, R., Epstein, R. B., Graham, T. C., & Thomas, E. D. (1970) · Transplantation · doi:10.1097/00007890-197003000-00007 · Cited by 315
Self-citationThomas, E. D., Buckner, C. D., Rudolph, R., Fefer, A., Storb, R. F., NEIMAN, P. E., Bryant, J. I., Chard, R. L., Clift, R. A., Epstein, R. B., et al. (1971) · Blood · doi:10.1182/blood.v38.3.267.267 · Cited by 145
Self-citationBortin, M. M. (1974) · Clinical immunobiology · doi:10.1016/b978-0-12-070002-8.50016-3 · Cited by 95
Cited by
Ford, R., & Eisenberg, S. (1990) · Nursing Clinics of North America · doi:10.1016/s0029-6465(22)02934-6 · Cited by 2,720
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Chronic graft-versus-host syndrome in man
Shulman, H. M., Sullivan, K. M., Weiden, P. L., McDonald, G. B., Striker, G. E., Sale, G. E., Hackman, R., Tsoi, M.-S., Storb, R., & Donnall Thomas, E. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90380-0 · Cited by 2,406
Self-citationDefining the Intensity of Conditioning Regimens: Working Definitions
Bacigalupo, A., Ballen, K., Rizzo, D., Giralt, S., Lazarus, H., Ho, V., Apperley, J., Slavin, S., Pasquini, M., Sandmaier, B. M., et al. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.07.004 · Cited by 1,816
Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts
Weiden, P. L., Flournoy, N., Thomas, E. D., Prentice, R., Fefer, A., Buckner, C. D., & Storb, R. (1979) · New England Journal of Medicine · doi:10.1056/nejm197905103001902 · Cited by 1,510
Self-citationMesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease
Ringdén, O., Uzunel, M., Rasmusson, I., Remberger, M., Sundberg, B., Lönnies, H., Marschall, H.-U., Dlugosz, A., Szakos, A., Hassan, Z., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000214462.63943.14 · Cited by 1,142
Weiden, P. L., Sullivan, K. M., Flournoy, N., Storb, R., Thomas, E. D., & The Seattle Marrow Transplant Team (1981) · New England Journal of Medicine · doi:10.1056/nejm198106183042507 · Cited by 1,081
Self-citationMarrow Transplantation from Related Donors Other Than HLA-Identical Siblings
Beatty, P. G., Clift, R. A., Mickelson, E. M., Nisperos, B. B., Flournoy, N., Martin, P. J., Sanders, J. E., Stewart, P., Buckner, C. D., Storb, R., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198509263131301 · Cited by 816
Self-citationMarrow Transplantation for Acute Nonlymphoblastic Leukemia in First Remission
Thomas, E. D., Buckner, C. D., Clift, R. A., Fefer, A., Johnson, F. L., Neiman, P. E., Sale, G. E., Sanders, J. E., Singer, J. W., Shulman, H., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197909133011109 · Cited by 641
Self-citationArmitage, J. O. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403243301206 · Cited by 601
Sullivan, K., Weiden, P., Storb, R., Witherspoon, R., Fefer, A., Fisher, L., Buckner, C., Anasetti, C., Appelbaum, F., & Badger, C. (1989) · Blood · doi:10.1182/blood.v73.6.1720.1720 · Cited by 599
Self-citationAllogeneic Bone‐Marrow Transplantation
Storb, R., & Thomas, E. D. (1983) · Immunological Reviews · doi:10.1111/j.1600-065x.1983.tb01069.x · Cited by 587
Self-citationGraft-versus-leukemia effects of transplantation and donor lymphocytes
Kolb, H.-J. (2008) · Blood · doi:10.1182/blood-2008-03-077974 · Cited by 582
A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment
Martin, P., Schoch, G., Fisher, L., Byers, V, Appelbaum, F., McDonald, G., Storb, R., & Hansen, J. (1991) · Blood · doi:10.1182/blood.v77.8.1821.1821 · Cited by 566
Self-citationPolymorphism in Sirpa modulates engraftment of human hematopoietic stem cells
Takenaka, K., Prasolava, T. K., Wang, J. C. Y., Mortin-Toth, S. M., Khalouei, S., Gan, O. I., Dick, J. E., & Danska, J. S. (2007) · Nature Immunology · doi:10.1038/ni1527 · Cited by 509
Sullivan, K., Weiden, P., Storb, R., Witherspoon, R., Fefer, A., Fisher, L., Buckner, C., Anasetti, C., Appelbaum, F., & Badger, C. (1989) · Blood · doi:10.1182/blood.v73.6.1720.bloodjournal7361720 · Cited by 446
Self-citationde Lima, M., Giralt, S., Thall, P. F., de Padua Silva, L., Jones, R. B., Komanduri, K., Braun, T. M., Nguyen, H. Q., Champlin, R., & Garcia‐Manero, G. (2010) · Cancer · doi:10.1002/cncr.25500 · Cited by 427
de Lima, M., Couriel, D., Thall, P. F., Wang, X., Madden, T., Jones, R., Shpall, E. J., Shahjahan, M., Pierre, B., Giralt, S., et al. (2004) · Blood · doi:10.1182/blood-2004-02-0414 · Cited by 415
Allogeneic Bone Marrow Transplantation in Multiple Myeloma
Gahrton, G., Tura, S., Ljungman, P., Belanger, C., Brandt, L., Cavo, M., Facon, T., Granena, A., Gore, M., Gratwohl, A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251802 · Cited by 378
Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor
Goldberg, M., Antin, J., Guinan, E., & Rappeport, J. (1986) · Blood · doi:10.1182/blood.v68.5.1114.1114 · Cited by 371
Hale, G., Bright, S., Chumbley, G., Hoang, T., Metcalf, D., Munro, A., & Waldmann, H. (1983) · Blood · doi:10.1182/blood.v62.4.873.873 · Cited by 360
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
Vetrie, D., Helgason, G. V., & Copland, M. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0230-9 · Cited by 349
Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision
Iqubal, A., Iqubal, M. K., Sharma, S., Ansari, M. A., Najmi, A. K., Ali, S. M., Ali, J., & Haque, S. E. (2019) · Life Sciences · doi:10.1016/j.lfs.2018.12.018 · Cited by 328
Pulmonary Complications of Bone Marrow Transplantation
Krowka, M. J., Rosenow, E. C., & Hoagland, H. C. (1985) · Chest · doi:10.1378/chest.87.2.237 · Cited by 306
Shulman, H. M., McDonald, G. B., Matthews, D., Doney, K. C., Kopecky, K. J., Gauvreau, J. M., & Thomas, E. D. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90911-7 · Cited by 286
Self-citationUnrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?
Grewal, S. S., Barker, J. N., Davies, S. M., & Wagner, J. E. (2003) · Blood · doi:10.1182/blood-2002-08-2510 · Cited by 284
Transplantation of Marrow from an Unrelated Donor to a Patient with Acute Leukemia
Hansen, J. A., Clift, R. A., Thomas, E. D., Buckner, C. D., Storb, R., & Giblett, E. R. (1980) · New England Journal of Medicine · doi:10.1056/nejm198009043031007 · Cited by 272
Self-citationThomas, E. D., Clift, R. A., Hersman, J., Sanders, J. E., Stewart, P., Buckner, C. D., Fefer, A., McGuffin, R., Smith, J. W., & Storb, R. (1982) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(82)90083-9 · Cited by 271
Self-citationAcute graft-versus-host disease
Malard, F., Holler, E., Sandmaier, B. M., Huang, H., & Mohty, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00438-1 · Cited by 268
Witherspoon, R., Storb, R., Ochs, H., Fluornoy, N., Kopecky, K., Sullivan, K., Deeg, J., Sosa, R., Noel, D., Atkinson, K., et al. (1981) · Blood · doi:10.1182/blood.v58.2.360.360 · Cited by 265
Self-citationScreening for Breast Cancer in 2018—What Should We be Doing Today?
Seely, J. M., & Alhassan, T. (2018) · Current Oncology · doi:10.3747/co.25.3770 · Cited by 258
Hematopoietic stem cell transplantation-50 years of evolution and future perspectives
Henig, I., & Zuckerman, T. (2014) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10162 · Cited by 209
Metadata
- Authors
- Thomas, E., Buckner, C., Banaji, M., Clift, R., Fefer, A., Flournoy, N., Goodell, B., Hickman, R., Lerner, K., Neiman, P., Sale, G., Sanders, J., Singer, J., Stevens, M., Storb, R., & Weiden, P.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1977-04-01
- Volume
- 49
- Issue
- 4
- Pages
- 511-533
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1522048276
- Cited by
- 979
- References
- 6
- FWCI
- 32.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.